We systematically compared cytokine-mediated increases or decreases in proliferation with globin gene and protein expression in adult human erythroblasts. Despite their opposite effects on growth, stem cell factor (SCF) and transforming growth factor-beta (TGF- 
Introduction
Well-defined mutations in the beta-globin locus on the short arm of chromosome 11 cause sickle-cell disease and beta-thalassemia. Those hemoglobinopathies are manifested soon after birth when fetal hemoglobin (HbF) expression is silenced and replaced by expression of adult hemoglobin (HbA). In some individuals with a hereditary persistence of fetal hemoglobin (HPFH), the fetal hemoglobin silencing phenomenon is prevented by other mutations within the beta-globin locus.
1,2 Individuals with adequate levels of fetal hemoglobin are partially protected from the clinical sequelae of sickle-cell disease or betathalassemia. The HPFH mutations in the beta-globin locus include deletional and nondeletional subtypes that cause either a heterocellular or pancellular expression of HbF.
HPFH also occurs in the absence of known mutations within the beta-globin locus. 3 In those families, other genomic regions are being investigated. Based upon the proven clinical benefits of HbF, understanding how specific HPFH mutations lead to dysregulated globin gene transcription remains a fundamental research goal.
In contrast to the extremely rare individuals with HPFH, humans more generally activate HbF expression in the setting of acute erythroid stress. Erythroid stress is characterized by increased erythropoiesis in response to tissue hypoxia, and acute stress has more profound effects upon HbF. 4 A molecular mechanism for stress-related increases in HbF has not yet been fully defined. Historically, studies of stress erythropoiesis led to the proposal that increased HbF results from proliferation of a "fetal clone". 5 Alternatively, it was suggested that increased HbF results primarily from accelerated differentiation of developmentally immature erythroblasts that were thought to normally express high levels of gamma-globin. 6 For personal use only. on . by guest www.bloodjournal.org From Mechanistic studies of growth-or signaling-related modulation of human fetal hemoglobin are currently not possible in murine models due to well-described differences in the erythroid stress response 7 as well as the inability to detect globin gene or protein expression in the circulating blood of NOD/SCID mice transplanted with human bone marrow. 8 For these reasons, cultures of primary human erythroblasts are the method of choice for defining relationships between erythroid growth, differentiation, and HbF. In the presence of erythropoietin (EPO) alone, low levels of HbF are detectable in a majority of proerythroblasts. As those cells undergo terminal maturation, detectable HbF is usually lost.
Stem cell factor (SCF) increases erythroblast growth and increases fetal hemoglobin. [9] [10] [11] Inhibitor studies suggest that the HbF-modulating effects of SCF require activation of the same signal transduction cascade involving MEK that is exploited by SCF to increase erythroid growth. 12 SCF modulation of HbF depends largely upon the regulated expression pattern of the SCF receptor (CD117, c-kit). 13 CD117 peaks at the proerythroblast stage of differentiation, and is thereafter lost during the final stages of maturation. As a result, SCF has a significantly less effect on HbF in mature erythroblasts. Furthermore, when SCF is added to progenitor populations, it inhibits their maturation. [13] [14] [15] Because of these reasons, SCF alone may not be sufficient to signal robust increases in HbF that persist during terminal maturation.
While not as well-characterized as SCF, transforming growth factor-beta (TGF-B) also signals increases in HbF among adult human erythroblasts. 16 However, TGF-B has distinctly opposite effects to SCF on erythroid growth and differentiation. TGF-B inhibits erythroid proliferation, and it is cytotoxic at higher concentrations. It also accelerates the differentiation of erythroid progenitors. 17, 18 We hypothesized that SCF and TGF-B together 
Materials and Methods
Primary erythroblast cultures. Informed consent was obtained for the collection of peripheral blood CD34+ cells. The cells were enumerated using an electronic cell counter (Coulter, Hialeah, FL) and cultured in medium containing 4 U/ml EPO (Amgen, Thousand Oaks, CA) as described previously (11) . The medium was supplemented with 50 ng/ml SCF (R&D Systems, Minneapolis, MN), or 1.25 ng/ml TGF-B1 (R&D Systems, Minneapolis, MN), or both in matched cultures. The concentrations of SCF and TGF-B used in this study were based upon dose-titration analyses over a 2-3 log range (data not shown). Cells obtained from at least three separate donors were used for all comparisons of growth and hemoglobin content.
Phenotyping studies. Cytospins were performed on days 0, 2, 4, 6, 8, 10, 12 and 14 and cell types were identified by morphology after Giemsa staining. Immunostaining with antibodies directed against glycophorin A (GPA), CD71 (Beckman Coulter, Miami, FL), HbF (Caltag Laboratories, Burlingame, CA) and HbA (Perkin Elmer Wallac, Norton, OH) were performed. A minimum of 5000 cells were analyzed using an EPICS ELITE ESP flow cytometer (Beckman Coulter, Hialeah, FL). Positive staining was defined by fluorescence at levels greater than two standard deviations above the isotypic controls. Quantitative PCR for gamma-and beta-globin expression. RNA was extracted from erythroblast pools using RNeasy Mini kit (Qiagen, Valencia, CA) as described previously. A quantitative real-time RT-PCR assay (RT-PCR) was carried out with gene-specific TaqMan® probes for both gamma-and beta-globin labeled with FAM and TAMRA dyes in a 7700 Sequence Dectector (Applied Biosystems, Foster City, CA). The PCR conditions were described previously. 12 A plasmid DNA encoding gamma-and beta-globin templates was used to generate the standard curve (20 to 2,000,000 copies) for determination of copy 
Results
Maturation patterns of cells cultured in EPO versus EST. While SCF has major effects upon gamma-globin gene expression in proerythroblasts, it also inhibits the maturation of those cells.
13-15 Therefore, we hypothesized that additional signals may be necessary to overcome the inhibited maturation associated with SCF. TGF-B was chosen to test this hypothesis due to its ability to accelerate erythroid differentiation. 17, 18 As shown in Figures 1 and 2, the addition of TGF-B to SCF resulted in a pattern of differentiation nearly identical to that seen in EPO alone. In EPO versus EST, a uniform population of proliferating proerythroblasts was observed after one week. By day 14, hemoglobinized normoblasts became the predominant population under both conditions.
In a separate comparison of erythroid maturation, matched cultures were examined by flow cytometry. Transferrin receptor (CD71) and glycophorin A (GPA) were compared on days 7 and 14. Those two membrane proteins are well-recognized markers of erythroid maturation. 19 Representative flow cytometric dot-plots are in Figure Growth-related patterns of hemoglobin production. Based upon the overall similarities of the erythroblasts generated after 14 days in EPO versus EST, analyses of cell proliferation and hemoglobin production were performed. As shown in Figure 3A , TGF-B significantly inhibited the proliferation of the cells compared with EPO alone (average cell counts in EPO = 3.1 x 10(5) cells/ml; EPO+TGF-B = 6.2 x 10(4) cells/ml; p<0.001). Due to its toxicity, measurable erythropoiesis was not detected in higher concentrations of TGF-B (data not shown). Adding SCF to the cultures had an opposite effect on growth. SCF significantly increased cell proliferation (EPO+SCF = 2.7 x 10(6) cells/ml; p<0.001). The combination of EPO + SCF + TGF-B resulted in proliferation of the erythroblasts to slightly higher levels than those found in EPO alone (EST = 4.5 X 10(5) cells/ml; p=0.03). Hence, the divergent effects of SCF and TGF-B erythropoiesis appeared to be balanced when the two cytokines were added together. This result further supports the data in As the primary target of TGF-B signaling, SMAD2 phosphorylation was also investigated to examine activation of that transcription factor in this culture system ( Figure   5 ). Phosphorylated SMAD2 associate with SMAD4 and translocate as a multicomplex to the nucleus where the heteromeric SMAD complex regulates transcription through its ability to interact with DNA binding and non-DNA binding transcription factors and cofactors.
21
SMAD2 was interrogated by Western analyses on cellular extracts under the same conditions as those used for MEK. In EPO alone or in EPO+SCF, SMAD2 phosphorylation was detected at low or background levels. When TGF-B was added to EPO or EPO+SCF, strong phosphorylation of SMAD2 was detected after 30 minutes.
For
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Gamma-globin mRNA expression patterns. In order to investigate the pattern of beta-and the gamma-globin transcription during the TGF-B mediated maturation of the cells, we initially performed quantitative PCR for comparative analyses on cell pools sampled on days 7 and 14. Mean values from matched cultures from five separate donors are in Table 1 . As shown, the average levels of beta-and gamma-globin mRNA were reduced as the cells underwent terminal differentiation between days 7 and 14. Cells grown in EST demonstrated a highly significant increase in the gamma/total globin percentage at day 7 (53.9+11.5%; p<0.001) and day 14 (25.8+20.9%; p<0.001) compared to 4.6+5.3% on day 7 and 1.4+1.1% on day 14 in EPO. On day 7, the increase in the gamma/total globin mRNA was due to an increase in gamma-globin mRNA and a significant reduction in beta-globin mRNA. On day 14, the relative decrease in beta-globin mRNA was no longer detected. While the total globin levels were increased in EPO versus EST, those increases did not achieve statistical significance.
In addition to studies of mRNA from pooled cells, we examined mRNA from one donor's sorted single cells on days 2, 5, 8, 11 and 14 using real-time PCR (Figure 6 ). On each of those days, mRNA from 48 sorted cells (24 cultured in EPO plus 24 cultured in EST; 240 cells in total) was studied. The patterns were consistent with those in Table 1 showing a rise in globin mRNA levels during the first week followed by progressively lower levels associated with terminal differentiation during the second week. By day 14, gammaglobin mRNA in EPO averaged only 60.7+176 molecules/cell compared with beta-globin mRNA averaging 7450+5060 molecules/cell. By comparison, gamma-globin in EST reached levels of 17,900+12,500 molecules/cell on day 8, and then declined to an average of 655+624 molecules/cell on day 14. As with the pools described in Table 1 , the significant For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 13 increase in gamma-globin mRNA detected midway through the culture was associated with a significant decrease in beta-globin mRNA. The divergent changes in the absolute levels of gamma-and beta-globin mRNA on culture day 8 ( Figure 6A , 6B) caused profound changes in the gamma/total globin ratio from 1.4+3.2% in EPO to 61.5+30.7% in EST ( Figure 6D ).
As a result of the decrease in beta-globin transcripts, the total globin mRNA levels were not significantly different in EPO versus EST ( Figure 6C) .
A major advantage for examining mRNA in single cells is the ability to directly determine the distributions of gamma-and beta-globin gene expression within the population. As shown in Figure 6F , pancellular beta-globin mRNA was detected in EPO and EST. Unlike beta-globin mRNA, gamma-globin mRNA was not detected in a pancellular distribution on any of the days in cultures supplemented with EPO alone. The maximum percentage (46% of cells examined expressing gamma-globin mRNA) was reached on day 5 in EPO, and then progressively declined to 17% by day 14. In EST, the distribution of gamma-globin mRNA was quite similar to that of beta-globin mRNA ( Figure 6E, 6F ).
Detection became pancellular by day 5, and that pattern persisted for the remainder of the culture period. Hence, expression of gamma-globin mRNA in a majority of cells was entirely cytokine-dependent.
Distribution of fetal hemoglobin. The pancellular expression of gamma-globin mRNA prompted us to study the distribution of HbF-expressing cells during erythroid maturation.
Representative HbF-based histograms from day 7 and day 14 analyses from several donors are in Figure 7 . In EPO alone, HbF was detected in 64% of the cells on day 7, and by day 14, HbF was reduced to 44%. The expression of HbF in EPO was generally low with 
Discussion
Based upon the growing body of evidence presented here and elsewhere, we propose that expression of gamma-globin mRNA and HbF in normal adult human erythroblasts is controlled by growth and related signal transduction. We previously identified EPOsupplemented culture conditions that lead to production of hemoglobinized populations of erythroblasts with low levels of HbF. 13 In that study, HbF production was silenced in a majority of the cells as they underwent a major growth transition at the proerythroblast stage toward terminal differentiation. To further examine the possible relationship between erythroblast growth and HbF, additional growth-promoting cytokines were screened. SCF promoted the growth of CD117+ proerythroblasts and increased the level and distribution of HbF in those cells. However, SCF inhibited the maturation of those cells. In this study, we determined that TGF-B also increases HbF production albeit to a lower extent than SCF.
However, TGF-B inhibited the proliferation of the cells. When added together, SCF and
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 15 TGF-B signaled balanced effects on growth, and the erythroblast populations were nearly identical to those arising in cultures containing EPO alone. Despite the similarities in cell number, immunophenotype, and morphology, dramatic differences were identified in the globin expression patterns in EPO versus EST. EST signaled high-level expression of HbF that persisted among the entire population of mature, hemoglobinized cells.
We also determined that the significant rise in HbF was associated with changes in globin mRNA levels using quantitative PCR. In EPO alone, beta-globin mRNA levels rose to extremely high levels during the first culture week, but declined as the cells underwent terminal maturation. Interestingly, the biphasic pattern of beta-globin mRNA resembled that previously demonstrated for the pattern of cells in the S-phase of cell-cycle. 11 The maximum levels of cell cycling and globin gene expression coincided with the proerythroblast stage of differentiation. In contrast to beta-globin mRNA, gamma-globin mRNA levels and distribution were lower in EPO alone. When SCF and TGF-B were added to the culture medium, several significant changes in the globin mRNA levels were observed. The gamma-globin mRNA levels rose and became dominant in proerythroblasts. The robust increase in gamma-globin mRNA was associated with a significant decrease in beta-globin mRNA. The balanced changes in gamma-and beta-globin mRNA levels may be indicative of a mechanism that controls the total level of transcription with resulting competition between the two genes. The combined levels of gamma-and beta-globin mRNA were not significantly different under the two culture conditions. Importantly, gamma-globin mRNA was present in >90% of the cells cultured in EST from day 5 onward. Therefore, molecular mechanisms must exist for a signaled activation of pancellular gamma-globin mRNA expression to be maintained throughout several mitotic divisions. Hence, chance or
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From inheritance are not the sole determinants of gamma-globin gene activation in primary adult human erythroblasts. 22 These signaled increases in gamma-globin mRNA and fetal hemoglobin were closely associated with events that encompass erythropoiesis. At the cellular level, we found no evidence that the combination of SCF and TGF-B act by recruiting a separate population of fetal cells. Instead, their effects appear to be mediated by balanced increases in growth and differentiation. It was previously demonstrated that SCF acts primarily by increasing gamma-globin mRNA levels at the proerythroblast stage of development. Our data suggest that TGF-B permitted or promoted a reversal of SCF-inhibited differentiation. With regard to signal transduction, it was previously shown that MEK activation is necessary for SCF mediated increases in HbF. Here we demonstrated that SCF+TGF-B signaled increases in HbF are associated with a combination of MEK and SMAD2 phosphorylation. In addition to its primary mechanism of activating SMAD transcription factors, 21 TGF-B may also act by increasing cAMP levels. 23 Preliminary studies with this culture system suggest that an adenylate cyclase-dependent mechanism may be involved in regulating HbF (data not shown 
